Latest News

Pfizer buying Medivation in deal valued at about $14B

Pfizer will pay about $ 14 billion in cash for the cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio.
The Daily Star >> Live News

Leave a Reply

Your email address will not be published. Required fields are marked *

*